for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Lannett Anticipates Biosimilar Application For Insulin Glargine To Be Submitted By 2022 End

June 11 (Reuters) - Lannett Company Inc:

* LANNETT PROVIDES UPDATE ON CLINICAL ADVANCEMENT OF BIOSIMILAR INSULIN GLARGINE, FOLLOWING FDA MEETING

* LANNETT COMPANY INC - ANTICIPATES BIOSIMILAR APPLICATION FOR INSULIN GLARGINE TO BE SUBMITTED BY END OF CALENDAR YEAR 2022

* LANNETT - FDA PROVIDED POSITIVE FEEDBACK ON CLINICAL AND CMC ADVANCEMENT OF BIOSIMILAR INSULIN GLARGINE THAT WAS CONSISTENT WITH CO’S EXPECTATIONS Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up